Tango Therapeutics (TNGX) Income towards Parent Company (2020 - 2026)
Tango Therapeutics (TNGX) posted quarterly Income towards Parent Company of -$45.5 million for Q1 2026, down 14.14% year-over-year from -$53.0 million in Q1 2025, and down 17.46% quarter-over-quarter from -$38.7 million in Q4 2025.
Tango Therapeutics (TNGX) Income towards Parent Company (2020 - 2026) Analysis & Trends
Tango Therapeutics' Income towards Parent Company history runs 7 years deep, the most recent figure standing at -$45.5 million for Q1 2026.
- In Q1 2026, Income towards Parent Company fell 14.14% year-over-year to -$45.5 million; the TTM figure through Mar 2026 stood at -$107.2 million (up 18.93% YoY), while the FY2025 annual figure was -$101.6 million, up 22.03% from the prior year.
- Income towards Parent Company for Q1 2026 stood at -$45.5 million, down from -$38.7 million in the prior quarter.
- The five-year high for Income towards Parent Company was $15.9 million in Q3 2025, with the low at -$45.5 million in Q1 2026.
- The 5-year median for Income towards Parent Company is -$29.1 million (2022), against an average of -$28.7 million.
- The sharpest annual moves came in 2022 and 2025: Income towards Parent Company sank 453.26% in 2022, then surged 154.46% in 2025.
- Tango Therapeutics' Income towards Parent Company stood at -$29.1 million in 2022, then declined by 5.58% to -$30.7 million in 2023, then declined by 22.59% to -$37.7 million in 2024, then declined by 2.86% to -$38.7 million in 2025, then decreased by 17.46% to -$45.5 million in 2026.
- Business Quant data shows TNGX's Income towards Parent Company at -$45.5 million in Q1 2026, -$38.7 million in Q4 2025, and $15.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Tango Therapeutics | 4.32 Bn | 3.30 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -55.34 Mn |
| Mar 31, 2026 | -45.51 Mn |
| Dec 31, 2025 | -38.75 Mn |
| Sep 30, 2025 | 15.88 Mn |
| Jun 30, 2025 | -38.85 Mn |
| Mar 31, 2025 | -39.88 Mn |
| Dec 31, 2024 | -37.67 Mn |
| Sep 30, 2024 | -29.17 Mn |
| Jun 30, 2024 | -25.55 Mn |
| Mar 31, 2024 | -37.91 Mn |
| Dec 31, 2023 | -30.73 Mn |
| Sep 30, 2023 | -22.26 Mn |
| Jun 30, 2023 | -20.75 Mn |
| Mar 31, 2023 | -28.01 Mn |
| Dec 31, 2022 | -29.11 Mn |
| Sep 30, 2022 | -29.05 Mn |
| Jun 30, 2022 | -24.86 Mn |
| Mar 31, 2022 | -25.21 Mn |
| Dec 31, 2021 | -22.05 Mn |
| Sep 30, 2021 | -19.59 Mn |